CRP and COVID-19: Notably, for PCSK9 inhibitors, another class of lipid-lowering drugs that significantly decreases LDL-C but not inflammatory markers like CRP (113, 114), evidence is lacked so far regarding their possible benefits on COVID-19 outcomes, while deeper investigation is needed.